RxDoctor Payments Data

Aaron Lockmiller, NP

Nurse Practitioner · Clovis, NMNPI 1417571258

Payments from drug & device makers

$153in general payments, 2019–2025

Across 9 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$41
  • Mylan Specialty L.p.$33
  • Amarin Pharma, Inc.$24
  • Johnson & Johnson$23
  • Lilly USA, LLC$16
  • Viatris Specialty LLC$16

What the payments were for

  • Food & beverage$153100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$153 in reported general payments places this provider in the 65th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$168,155
Medicare patients
407
Services billed
3,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin84$72,641
OzempicSemaglutide58$63,976
EliquisApixaban79$62,697
MounjaroTirzepatide40$51,188
FarxigaDapagliflozin Propanediol50$38,388
TrulicityDulaglutide22$27,512
XareltoRivaroxaban26$26,020
RybelsusSemaglutide15$19,823
JanuviaSitagliptin Phosphate29$19,237
MyrbetriqMirabegron34$15,702
Spiriva RespimatTiotropium Bromide23$11,377
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,273
Spiriva HandihalerTiotropium Bromide18$11,040
Incruse ElliptaUmeclidinium Bromide20$7,002
Breo ElliptaFluticasone/Vilanterol15$6,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$41$83,80073 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin N$16$80,18873 claims
Johnson & JohnsonXarelto$23$26,02026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Clovis

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →